Homeostatic Proliferation and Memory CD8 T Cells

稳态增殖和记忆 CD8 T 细胞

基本信息

  • 批准号:
    8051809
  • 负责人:
  • 金额:
    $ 35.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-05-01 至 2013-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Generation of T cell memory is a critical component of protective immunity. While memory T cells normally arise following priming of naove T cells with foreign antigen, a distinct pathway can also generate functional memory T cells - as a consequence of homeostatic proliferation in a lymphopenic environment. Study of memory T cells produced by homeostatic proliferation ("HP memory" cells) is relevant to understanding the essential requirements for memory T cell differentiation, and also for assessing the relevance of this alternative pathway in establishing protective immunity in immunocompromized individuals. Using mouse models, we recently showed that both "conventional memory" T cells (i.e. those generated through priming) and HP memory CD8 T cells offer similar protective immunity against a pathogen. However, while experimental models of lymphopenia are well studied, much less is known about HP memory cells produced during natural situations of lymphopenia (in the neonatal period and after acute infections). We explore this in three aims, studying: the function of HP memory CD8 T cells generated in "natural" lymphopenic environments (Aim 1): the presence and function of antigen specific endogenous HP memory CD8 T cells (Aim 2) and the role of neonatal lymphopenia and endogenous HP CD8 memory T cells in supporting immune reactivity of the young animals (Aim 3). The goal of these studies is to determine whether foreign antigen responsive HP memory CD8 T cells are generated during natural bouts of lymphopenia, and whether they contribute to the adaptive immune response. PUBLIC HEALTH RELEVENCE: Memory T cells are a critical element in immune protection against pathogens. Memory cells are generated as a consequence of immune priming, but are also generated during the response to immuno-deficiency, or lymphopenia, which occurs physiologically during development and also as a consequence of infections. The significance of the proposal is in learning how such "homeostatic" mechanisms may foster establishment of protective "memory- like" CD8 T cells system in immunocompromized individuals, including the very young.
描述(由申请人提供):T 细胞记忆的产生是保护性免疫的关键组成部分。虽然记忆 T 细胞通常是在用外来抗原启动幼稚 T 细胞后产生的,但独特的途径也可以产生功能性记忆 T 细胞 - 作为淋巴细胞减少环境中稳态增殖的结果。对稳态增殖产生的记忆 T 细胞(“HP 记忆”细胞)的研究有助于了解记忆 T 细胞分化的基本要求,也有助于评估这种替代途径在免疫受损个体中建立保护性免疫的相关性。我们最近使用小鼠模型表明,“传统记忆”T 细胞(即通过启动产生的细胞)和 HP 记忆 CD8 T 细胞都提供类似的针对病原体的保护性免疫。然而,虽然淋巴细胞减少症的实验模型得到了充分研究,但对淋巴细胞减少症自然情况下(新生儿期和急性感染后)产生的 HP 记忆细胞知之甚少。我们通过三个目标对此进行探索,研究:在“自然”淋巴细胞减少环境中生成的 HP 记忆 CD8 T 细胞的功能(目标 1):抗原特异性内源性 HP 记忆 CD8 T 细胞的存在和功能(目标 2)以及新生儿淋巴细胞减少和内源性 HP CD8 记忆 T 细胞在支持幼年动物免疫反应中的作用(目标 3)。这些研究的目的是确定外源抗原反应性 HP 记忆 CD8 T 细胞是否在淋巴细胞减少症自然发作期间产生,以及它们是否有助于适应性免疫反应。公共卫生相关性:记忆 T 细胞是针对病原体的免疫保护的关键要素。记忆细胞是由于免疫启动而产生的,但也在对免疫缺陷或淋巴细胞减少的反应过程中产生,免疫缺陷或淋巴细胞减少是在发育过程中生理上发生的,也是感染的结果。该提案的意义在于了解这种“稳态”机制如何促进免疫功能低下个体(包括幼儿)建立保护性“记忆样”CD8 T 细胞系统。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN C JAMESON其他文献

STEPHEN C JAMESON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN C JAMESON', 18)}}的其他基金

Regulation of T cell responses by P2RX7
P2RX7 对 T 细胞反应的调节
  • 批准号:
    10393494
  • 财政年份:
    2019
  • 资助金额:
    $ 35.8万
  • 项目类别:
Regulation of T cell responses by P2RX7
P2RX7 对 T 细胞反应的调节
  • 批准号:
    10605308
  • 财政年份:
    2019
  • 资助金额:
    $ 35.8万
  • 项目类别:
The impact of IL-4 on the CD8 T cell response to pathogens
IL-4对CD8 T细胞对病原体反应的影响
  • 批准号:
    8293998
  • 财政年份:
    2012
  • 资助金额:
    $ 35.8万
  • 项目类别:
The impact of IL-4 on the CD8 T cell response to pathogens
IL-4对CD8 T细胞对病原体反应的影响
  • 批准号:
    8424945
  • 财政年份:
    2012
  • 资助金额:
    $ 35.8万
  • 项目类别:
Homeostatic Proliferation and Memory CD8 T Cells
稳态增殖和记忆 CD8 T 细胞
  • 批准号:
    8660594
  • 财政年份:
    2008
  • 资助金额:
    $ 35.8万
  • 项目类别:
Homeostatic Proliferation and Memory CD8 T Cells
稳态增殖和记忆 CD8 T 细胞
  • 批准号:
    7609195
  • 财政年份:
    2008
  • 资助金额:
    $ 35.8万
  • 项目类别:
Homeostatic Proliferation and Memory CD8 T Cells
稳态增殖和记忆 CD8 T 细胞
  • 批准号:
    8261080
  • 财政年份:
    2008
  • 资助金额:
    $ 35.8万
  • 项目类别:
Homeostatic Proliferation and Memory CD8 T Cells
稳态增殖和记忆 CD8 T 细胞
  • 批准号:
    8502797
  • 财政年份:
    2008
  • 资助金额:
    $ 35.8万
  • 项目类别:
Homeostatic Proliferation and Memory CD8 T Cells
稳态增殖和记忆 CD8 T 细胞
  • 批准号:
    8822792
  • 财政年份:
    2008
  • 资助金额:
    $ 35.8万
  • 项目类别:
Homeostatic Proliferation and Memory CD8 T Cells
稳态增殖和记忆 CD8 T 细胞
  • 批准号:
    7799139
  • 财政年份:
    2008
  • 资助金额:
    $ 35.8万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 35.8万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 35.8万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 35.8万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 35.8万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 35.8万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 35.8万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 35.8万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 35.8万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 35.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了